Nxera Pharma Co., Ltd. SOLTF
Set alert
8.50 USD 0.00 0.00%
At close · Oct 30
8.50 Day range 8.50
4.90 52-week range 8.50
- YTD
- +55.11%
- 1 year
- +38.44%
- Open
- 8.50
- Prev close
- 8.50
- Mkt cap
- 776.69M
- Vol
- 100
- Avg vol
- 85
- EPS
- -0.40
- P/E
- 0.00
More statistics
- Low
- 8.50
- High
- 8.50
3M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| RSI: Overbought | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| RSI: Overbought | Sep 3, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
News
- Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript
- Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript
- Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
- Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
- Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
- Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
- Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
- Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
- Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF) Short Interest Update
- Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Your note
Sign in to keep a note on SOLTF — it syncs with the Stock Master app.